HC Wainwright Has Weak Forecast for Nuvation Bio Q1 Earnings

Nuvation Bio Inc. (NYSE:NUVB) – Investment analysts at HC Wainwright reduced their Q1 2026 EPS estimates for shares of Nuvation Bio in a note issued to investors on Tuesday, March 3rd. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.13) per share for the quarter, down from their previous estimate of ($0.11). HC Wainwright has a “Buy” rating and a $17.00 price objective on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Nuvation Bio’s Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.44) EPS.

Nuvation Bio (NYSE:NUVB) last issued its earnings results on Monday, March 2nd. The company reported ($0.11) EPS for the quarter, hitting the consensus estimate of ($0.11). Nuvation Bio had a negative return on equity of 57.48% and a negative net margin of 325.31%.The business had revenue of $41.87 million during the quarter, compared to analysts’ expectations of $36.82 million.

Several other equities analysts have also recently weighed in on the company. Truist Financial set a $13.00 target price on Nuvation Bio in a research note on Tuesday, January 27th. UBS Group decreased their price target on shares of Nuvation Bio from $10.00 to $7.00 and set a “neutral” rating for the company in a report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nuvation Bio in a research report on Thursday, January 22nd. Royal Bank Of Canada upped their price objective on shares of Nuvation Bio from $12.00 to $13.00 and gave the company an “outperform” rating in a research note on Tuesday. Finally, Citizens Jmp set a $10.00 target price on shares of Nuvation Bio in a research report on Thursday, November 20th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.44.

Nuvation Bio Stock Down 4.0%

NYSE:NUVB opened at $4.55 on Thursday. The business’s fifty day moving average price is $6.35 and its 200 day moving average price is $5.53. The firm has a market capitalization of $1.56 billion, a price-to-earnings ratio of -7.58 and a beta of 1.50. The company has a current ratio of 6.95, a quick ratio of 8.39 and a debt-to-equity ratio of 0.15. Nuvation Bio has a 1-year low of $1.54 and a 1-year high of $9.75.

Hedge Funds Weigh In On Nuvation Bio

Several hedge funds have recently bought and sold shares of NUVB. Rangeley Capital LLC bought a new stake in Nuvation Bio during the second quarter worth about $25,000. Parallel Advisors LLC raised its stake in shares of Nuvation Bio by 51.9% in the third quarter. Parallel Advisors LLC now owns 7,597 shares of the company’s stock valued at $28,000 after acquiring an additional 2,597 shares during the last quarter. Cetera Investment Advisers acquired a new position in shares of Nuvation Bio in the 2nd quarter worth approximately $29,000. Captrust Financial Advisors bought a new stake in Nuvation Bio during the 2nd quarter worth approximately $32,000. Finally, Swiss Life Asset Management Ltd bought a new stake in Nuvation Bio during the 3rd quarter worth approximately $39,000. 61.67% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Nuvation Bio

Here are the key news stories impacting Nuvation Bio this week:

• Positive Sentiment: Nuvation announced a transition to commercial stage with progress on Iptrozi and safusidenib, marking operational progress toward revenue generation and reducing pure clinical-stage risk. Nuvation Bio Transitions To Commercial Stage With Iptrozi And Safusidenib Progress
• Positive Sentiment: Royal Bank of Canada raised its price target on NUVB to $13, providing another independent valuation boost that can support upside sentiment. Royal Bank Of Canada Boosts Nuvation Bio (NYSE:NUVB) Price Target to $13.00
• Positive Sentiment: H.C. Wainwright maintained a Buy rating and a $17 target on NUVB, signaling continued analyst conviction despite model revisions — a supportive counterweight for investor sentiment. H.C. Wainwright Sticks to Its Buy Rating for Nuvation Bio (NUVB)
• Neutral Sentiment: Industry coverage flagged commercialization and partner execution risks for taletrectinib — useful context for evaluating upside but not a direct new corporate action. Nuvation Bio’s Taletrectinib Outlook Clouded by Commercialization and Partner Execution Risks
• Negative Sentiment: H.C. Wainwright reduced EPS estimates across Q1–Q4 and cut FY2026 EPS forecasts (e.g., FY now -$0.44 vs prior -$0.35). Earnings downgrades signal weaker near-term profitability expectations and likely contributed to downward price pressure.
• Negative Sentiment: UBS lowered its expectations for NUVB, adding to sell-side skepticism that can amplify volatility and limit near-term upside. UBS Group Has Lowered Expectations for Nuvation Bio (NYSE:NUVB) Stock Price
• Negative Sentiment: A shareholder law firm (Johnson Fistel) announced an investigation into potential securities-law claims involving Nuvation and its officers — a legal probe that increases headline risk and can weigh on investor confidence. Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel

About Nuvation Bio

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.